Immunoreactivity of anti-gelsolin antibodies: Implications for biomarker validation

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Haverland, Nicole ^a   Pottiez, Gwënaël ^a   Wiederin, Jayme ^a   Ciborowski, Pawel ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELSOLIN; GELSOLIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; BIOLOGICAL MARKER;

ANTIBODY AFFINITY; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; HAPLORHINI; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; IN VITRO STUDY; MACROPHAGE; NONHUMAN; VALIDATION PROCESS; AFFINITY CHROMATOGRAPHY; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; CEREBROSPINAL FLUID; CHEMISTRY; IMMUNOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; REPRODUCIBILITY; TITRIMETRY; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, LIQUID; GELSOLIN; HAPLORHINI; HUMANS; MASS SPECTROMETRY; REPRODUCIBILITY OF RESULTS; TITRIMETRY;

EID: 78650294057     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-137     Document Type: Article

References (34)

1. Silberring J, Ciborowski P. Biomarker discovery and clinical proteomics. Trends Analyt Chem 29:128. 10.1016/j.trac.2009.11.007, 20174458.
2. Ciborowski P. Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches. Biomark Med 2009, 3:771-785. 10.2217/bmm.09.63, 20477714.
3. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867. 10.1074/mcp.R200007-MCP200, 12488461.
4. Bell AW, Deutsch EW, Au CE, Kearney RE, Beavis R, Sechi S, Nilsson T, Bergeron JJ. A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods 2009, 6:423-430. 10.1038/nmeth.1333, 2785450, 19448641.
5. Karp NA, Lilley KS. Design and analysis issues in quantitative proteomics studies. Proteomics 2007, 7(Suppl 1):42-50. 10.1002/pmic.200700683, 17893850.
6. Al-Shahib A, Misra R, Ahmod N, Fang M, Shah H, Gharbia S. Coherent pipeline for biomarker discovery using mass spectrometry and bioinformatics. BMC Bioinformatics 11:437. 10.1186/1471-2105-11-437, 2939613, 20796299.
7. Cummings J, Ward TH, Dive C. Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov Today 2010, 15:816-825. 10.1016/j.drudis.2010.07.006, 20708097.
8. Valeron PF, Chirino R, Fernandez L, Torres S, Navarro D, Aguiar J, Cabrera JJ, Diaz-Chico BN, Diaz-Chico JC. Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. Int J Cancer 1996, 65:129-133. 10.1002/(SICI)1097-0215(19960117)65:2<129::AID-IJC1>3.0.CO;2-0, 8567106.
9. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AM, Sweep CG. EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers 2000, 15:184-191.
10. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. Jama 2002, 287:1671-1679. 10.1001/jama.287.13.1671, 11926891.
11. Tremblay RR, Coulombe E, Cloutier S, Brunet C, Deperthes D, Frenette G, Dube JY. Assessment of the trypsin-like human prostatic kallikrein, also known as hK2, in the seminal plasma of infertile men: respective contributions of an ELISA procedure and of Western blotting. J Lab Clin Med 1998, 131:330-335. 10.1016/S0022-2143(98)90183-4, 9579386.
12. Imafuku Y, Omenn GS, Hanash S. Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers 2004, 20:149-153.
13. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006, 5:573-588.
14. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009, 55:1108-1117. 10.1373/clinchem.2009.123935, 2865473, 19372185.
15. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1229-1239. 10.1016/j.jchromb.2008.11.013, 19041286.
16. Han B, Higgs RE. Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. Brief Funct Genomic Proteomic 2008, 7:340-354. 10.1093/bfgp/eln032, 18579614.
17. Rozek W, Horning J, Anderson J, Ciborowski P. Sera Proteomic Biomarker Profiling in HIV-1 Infected Subjects with Cognitive Impairment. Proteomics - Clinical Applications 2008, 2:1498-1507. 10.1002/prca.200780114, 21136797.
18. Rozek W, Ricardo-Dukelow M, Holloway S, Gendelman HE, Wojna V, Melendez LM, Ciborowski P. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res 2007, 6:4189-4199. 10.1021/pr070220c, 17929958.
19. Wiederin JL, Donahoe RM, Anderson JR, Yu F, Fox HS, Gendelman HE, Ciborowski PS. Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques. J Proteome Res 2010, 9:4721-4731. 10.1021/pr1004345, 20677826.
20. Pottiez G, Haverland N, Ciborowski P. Mass spectrometric characterization of gelsolin isoforms. Rapid Commun Mass Spectrom 2010, 24:2620-2624. 10.1002/rcm.4681, 20740538.
21. Donahoe RM, O'Neil SP, Marsteller FA, Novembre FJ, Anderson DC, Lankford-Turner P, McClure HH. Probable deceleration of progression of Simian AIDS affected by opiate dependency: studies with a rhesus macaque/SIVsmm9 model. J Acquir Immune Defic Syndr 2009, 50:241-249. 10.1097/QAI.0b013e3181967354, 19194320.
22. Gendelman HE, Leonard JM, Dutko F, Koenig S, Khillan J, Meltzer MS. Immunopathogenesis of human immunodeficiency virus infection in the central nervous system. Ann Neurol 1988, 23(Suppl):S78-81. 10.1002/ana.410230721, 3348602.
23. Ciborowski P, Kadiu I, Rozek W, Smith L, Bernhardt K, Fladseth M, Ricardo-Dukelow M, Gendelman HE. Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology 2007, 363:198-209. 10.1016/j.virol.2007.01.013, 1993545, 17320137.
24. Ciborowski P, Enose Y, Mack A, Fladseth M, Gendelman HE. Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. J Neuroimmunol 2004, 157:11-16. 10.1016/j.jneuroim.2004.08.033, 15579275.
25. Wiederin J, Rozek W, Duan F, Ciborowski P. Biomarkers of HIV-1 associated dementia: proteomic investigation of sera. Proteome Sci 2009, 7:8. 10.1186/1477-5956-7-8, 2666658, 19292902.
26. Lind SE, Janmey PA. Human plasma gelsolin binds to fibronectin. J Biol Chem 1984, 259:13262-13266.
27. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 56:177-185. 10.1373/clinchem.2009.126706, 19884488.
28. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245. 10.1002/pmic.200500358, 16104056.
29. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983. 10.1038/nbt1235, 16900146.
30. Rodriguez-Pineiro AM, Blanco-Prieto S, Sanchez-Otero N, Rodriguez-Berrocal FJ, de la Cadena MP. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics 73:1511-1522. 10.1016/j.jprot.2010.03.005, 20230924.
31. Lee PS, Bhan I, Thadhani R. The potential role of plasma gelsolin in dialysis-related protein-energy wasting. Blood Purif 29:99-101. 10.1159/000245632, 20093811.
32. Ohnishi M, Matsumoto T, Nagashio R, Kageyama T, Utsuki S, Oka H, Okayasu I, Sato Y. Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol Int 2009, 59:797-803. 10.1111/j.1440-1827.2009.02447.x, 19883430.
33. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004, 3:235-244. 10.1021/pr034086h, 15113099.
34. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641. 10.1038/nbt.1546, 2855883, 19561596.